Bone disease in primary biliary cirrhosis: Histologic features and response to 25-hydroxyvitamin D

H. F. Herlong, Robert R. Recker, W. C. Maddrey

Research output: Contribution to journalArticle

132 Citations (Scopus)

Abstract

Fifteen female patients with primary biliary cirrhosis were evaluated for vitamin D status and evidence of metabolic bone disease. Full-thickness iliac crest bone biopsy specimens with histomorphometric analysis after double tetracycline labeling were performed before and after 1 yr of treatment with oral 25-hydroxyvitamin D (100 μg/day). Initially, serum 25-hydroxyvitamin D levels were low (25 ng/ml) in all patients within 3 mo. Serum parathyroid hormone levels were low normal or not detectable in all patients and did not change with therapy. No patient had a fracture during the treatment. No evidence of osteomalacia was found initially or in follow-up study in any patient. Follow-up histomorphometric analysis at the end of the 1-yr treatment showed that bone volume decreased during the study interval despite therapy (p <0.001). Photon beam densitometry confirmed the loss in trabecular density of the radius over the study interval (p <0.03). The mean fractional osteoid surface was not increased initially and did not change with therapy. The mean linear bone appositional rate as measured by double tetracycline labeling was not decreased initially and did not change with therapy. It was concluded that in moderate to severe primary biliary cirrhosis, initial 25-hydroxyvitamin D levels are low and are rapidly corrected by oral 25-hydroxyvitamin D. These patients have significant osteoporosis which progresses despite 25-hydroxyvitamin D.

Original languageEnglish
Pages (from-to)103-108
Number of pages6
JournalGastroenterology
Volume83
Issue number1 I
StatePublished - 1982

Fingerprint

Biliary Liver Cirrhosis
Bone Diseases
Tetracycline
Bone and Bones
Therapeutics
Osteomalacia
Densitometry
Metabolic Bone Diseases
25-hydroxyvitamin D
Parathyroid Hormone
Serum
Photons
Vitamin D
Osteoporosis
Biopsy

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Bone disease in primary biliary cirrhosis : Histologic features and response to 25-hydroxyvitamin D. / Herlong, H. F.; Recker, Robert R.; Maddrey, W. C.

In: Gastroenterology, Vol. 83, No. 1 I, 1982, p. 103-108.

Research output: Contribution to journalArticle

@article{d22f1002f80745af830d763a5d885f3b,
title = "Bone disease in primary biliary cirrhosis: Histologic features and response to 25-hydroxyvitamin D",
abstract = "Fifteen female patients with primary biliary cirrhosis were evaluated for vitamin D status and evidence of metabolic bone disease. Full-thickness iliac crest bone biopsy specimens with histomorphometric analysis after double tetracycline labeling were performed before and after 1 yr of treatment with oral 25-hydroxyvitamin D (100 μg/day). Initially, serum 25-hydroxyvitamin D levels were low (25 ng/ml) in all patients within 3 mo. Serum parathyroid hormone levels were low normal or not detectable in all patients and did not change with therapy. No patient had a fracture during the treatment. No evidence of osteomalacia was found initially or in follow-up study in any patient. Follow-up histomorphometric analysis at the end of the 1-yr treatment showed that bone volume decreased during the study interval despite therapy (p <0.001). Photon beam densitometry confirmed the loss in trabecular density of the radius over the study interval (p <0.03). The mean fractional osteoid surface was not increased initially and did not change with therapy. The mean linear bone appositional rate as measured by double tetracycline labeling was not decreased initially and did not change with therapy. It was concluded that in moderate to severe primary biliary cirrhosis, initial 25-hydroxyvitamin D levels are low and are rapidly corrected by oral 25-hydroxyvitamin D. These patients have significant osteoporosis which progresses despite 25-hydroxyvitamin D.",
author = "Herlong, {H. F.} and Recker, {Robert R.} and Maddrey, {W. C.}",
year = "1982",
language = "English",
volume = "83",
pages = "103--108",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "1 I",

}

TY - JOUR

T1 - Bone disease in primary biliary cirrhosis

T2 - Histologic features and response to 25-hydroxyvitamin D

AU - Herlong, H. F.

AU - Recker, Robert R.

AU - Maddrey, W. C.

PY - 1982

Y1 - 1982

N2 - Fifteen female patients with primary biliary cirrhosis were evaluated for vitamin D status and evidence of metabolic bone disease. Full-thickness iliac crest bone biopsy specimens with histomorphometric analysis after double tetracycline labeling were performed before and after 1 yr of treatment with oral 25-hydroxyvitamin D (100 μg/day). Initially, serum 25-hydroxyvitamin D levels were low (25 ng/ml) in all patients within 3 mo. Serum parathyroid hormone levels were low normal or not detectable in all patients and did not change with therapy. No patient had a fracture during the treatment. No evidence of osteomalacia was found initially or in follow-up study in any patient. Follow-up histomorphometric analysis at the end of the 1-yr treatment showed that bone volume decreased during the study interval despite therapy (p <0.001). Photon beam densitometry confirmed the loss in trabecular density of the radius over the study interval (p <0.03). The mean fractional osteoid surface was not increased initially and did not change with therapy. The mean linear bone appositional rate as measured by double tetracycline labeling was not decreased initially and did not change with therapy. It was concluded that in moderate to severe primary biliary cirrhosis, initial 25-hydroxyvitamin D levels are low and are rapidly corrected by oral 25-hydroxyvitamin D. These patients have significant osteoporosis which progresses despite 25-hydroxyvitamin D.

AB - Fifteen female patients with primary biliary cirrhosis were evaluated for vitamin D status and evidence of metabolic bone disease. Full-thickness iliac crest bone biopsy specimens with histomorphometric analysis after double tetracycline labeling were performed before and after 1 yr of treatment with oral 25-hydroxyvitamin D (100 μg/day). Initially, serum 25-hydroxyvitamin D levels were low (25 ng/ml) in all patients within 3 mo. Serum parathyroid hormone levels were low normal or not detectable in all patients and did not change with therapy. No patient had a fracture during the treatment. No evidence of osteomalacia was found initially or in follow-up study in any patient. Follow-up histomorphometric analysis at the end of the 1-yr treatment showed that bone volume decreased during the study interval despite therapy (p <0.001). Photon beam densitometry confirmed the loss in trabecular density of the radius over the study interval (p <0.03). The mean fractional osteoid surface was not increased initially and did not change with therapy. The mean linear bone appositional rate as measured by double tetracycline labeling was not decreased initially and did not change with therapy. It was concluded that in moderate to severe primary biliary cirrhosis, initial 25-hydroxyvitamin D levels are low and are rapidly corrected by oral 25-hydroxyvitamin D. These patients have significant osteoporosis which progresses despite 25-hydroxyvitamin D.

UR - http://www.scopus.com/inward/record.url?scp=0020075621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020075621&partnerID=8YFLogxK

M3 - Article

C2 - 6978827

AN - SCOPUS:0020075621

VL - 83

SP - 103

EP - 108

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 1 I

ER -